Coordinating and Data Management Center for Acquired Resistance to Therapy Network

获得性治疗耐药网络协调和数据管理中心

• 批准号: 10516537
• 负责人: DAVID W. GOODRICH
• 金额: $ 105.04万
• 依托单位: ROSWELL PARK CANCER INSTITUTE CORP
• 依托单位国家: 美国
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-09-01 至 2027-08-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10516537
• 关键词: Address; Adopted; Bioconductor; Bioinformatics; Biometry; Biostatistics Shared Resource; Cancer Center Support Grant; Clinical; Collaborations; Combined Modality Therapy; Communities; Comprehension; Computer software; Custom; Data; Data Management Resources; Data Science; Data Set; Data Storage and Retrieval; Databases; Development; Drug Kinetics; Drug resistance; Ecosystem; Ensure; Fostering; Funding; Goals; Hand; Immunooncology; Immunotherapy; Informatics; Information Technology; Infrastructure; Lead; Malignant Neoplasms; Methods; Multiomic Data; National Human Genome Research Institute; Patients; Pharmacodynamics; Police; Policies; Principal Investigator; Productivity; PubMed; Records; Reproducibility; Research; Research Personnel; Research Project Grants; Resistance; Resource Sharing; Resources; Services; Text; Therapeutic; Translating; United States National Institutes of Health; Visualization; base; biobank; biomedical informatics; cancer therapy; cloud based; community engagement; cost; data acquisition; data ecosystem; data harmonization; data integration; data management; data repository; data resource; data sharing; data sharing networks; data standards; drug sensitivity; experience; genomic data; improved; interoperability; multidisciplinary; open source; operation; outreach; pharmacokinetics and pharmacodynamics; pre-clinical; predictive marker; quality assurance; real time monitoring; repository; resistance mechanism; response; support network; therapy resistant; tool; translational oncology; tumor microenvironment; virtual

Project Summary The goal of our proposed Coordinating and Data Management Center (CDMC) application is to coordinate the activities across the Acquired Resistance to Therapy Network (ARTNet), and to manage, integrate and disseminate the data and resources generated through the network. Leveraging cutting-edge multi-disciplinary team approaches, we will support the ARTNet to inform new strategies that can be better translated to overcome significant challenges in acquired resistance to cancer therapies. Our strategy is to enhance the productivity of ARTNet investigators by fostering a collaborative and supportive research community, accelerate the progress of ARTNet research by reducing barriers to accessing analytical expertise, ensure the reproducibility of ARTNet data by deploying best practices for data acquisition and harmonization, and unleash the full potential of ARTNet activities by developing enhanced tools to enable resource sharing to the broader scientific community. First, we will provide a centralized administrative infrastructure to coordinate ARTNet activities, building upon our well-functioning infrastructure that currently coordinates network studies under the umbrella of the NCI Cancer Moonshot initiatives. Second, we will actively promote the ARTNet and engage in trans-consortium interactions, where we will leverage our demonstrable experience in Cross-Moonshot outreach and Bioconductor’s decades-long record in community engagement. Third, we will provide multidisciplinary analytical expertise to support ARTNet collaborative research, leveraging five of Roswell Park CCSG’s shared resources: Biostatistics, Bioinformatics, Biomedical Informatics, Pharmacokinetics/Pharmacodynamics, and Data Bank and BioRepository. Our analytical support will be provided at no cost to ARTNet investigators in need of analytical expertise, based on collaboration, transparency, and sharing. Fourth, we will develop improved data integration software and workflows to enhance ARTNet’s research capacity, capitalizing on our extensive track-record in developing NIH-supported Moonshot, Bioconductor and AnVIL ecosystems. The main deliverables from the proposed aims will be administrative and outreach support to coordinate network activities, facilitate network collaboration, and engage in interaction with the broader community (Aim 1); polices and infrastructures to ensure that all resources generated by the ARTNet will be findable in a centralized virtual resource sharing repository, and that all resources will be shared with the broader scientific community (Aim 2); workflows to ensure that all data generated by the ARTNet will be harmonized using standards interoperable with the broader cancer data ecosystem, analysis tools to integrate ARTNet data and facilitate cross-study analysis within and beyond the ARTNet, and multidisciplinary analytical supports to accelerate ARTNet research progress.(Aim 3).

项目概要 我们提出的协调和数据管理中心（CDMC）应用程序的目标是协调 跨获得性治疗耐药网络 (ARTNet) 的活动，以及管理、整合和 传播通过网络产生的数据和资源。充分利用前沿的多学科 团队方法，我们将支持 ARTNet 提供新策略，这些策略可以更好地转化为克服 对癌症治疗获得性耐药性的重大挑战。我们的战略是提高生产力 ARTNet 研究人员通过培养协作和支持性的研究社区，加快了进展 通过减少获取分析专业知识的障碍，确保 ARTNet 研究的可重复性 通过部署数据采集和协调的最佳实践来收集数据，并释放 ARTNet 的全部潜力 开发增强工具以实现更广泛的科学界资源共享的活动。 首先，我们将提供一个集中的管理基础设施来协调 ARTNet 活动， 我们运作良好的基础设施目前在 NCI 的保护下协调网络研究 癌症登月计划。第二，我们将积极推动ARTNet，从事跨联盟 互动，我们将利用我们在 Cross-Moonshot 推广方面的明显经验， Bioconductor 数十年来在社区参与方面的记录。第三，我们将提供多学科分析 利用 Roswell Park CCSG 的五个共享资源来支持 ARTNet 协作研究的专业知识： 生物统计学、生物信息学、生物医学信息学、药代动力学/药效学和数据库 生物储存库。我们将免费向需要分析的 ARTNet 调查人员提供分析支持 基于协作、透明度和共享的专业知识。第四，我们将开发改进的数据集成 软件和工作流程，以增强 ARTNet 的研究能力，利用我们在 开发 NIH 支持的 Moonshot、Bioconductor 和 AnVIL 生态系统。 拟议目标的主要成果将是行政和外展支持，以协调 网络活动，促进网络协作，并与更广泛的社区进行互动（目标 1）；政策和基础设施，以确保 ARTNet 生成的所有资源都可以在 集中的虚拟资源共享存储库，所有资源将与更广泛的科学共享 社区（目标 2）；工作流程，以确保 ARTNet 生成的所有数据将使用协调一致 可与更广泛的癌症数据生态系统互操作的标准、集成 ARTNet 数据的分析工具和 促进 ARTNet 内外的交叉研究分析，并提供多学科分析支持 加速ARTNet研究进展。（目标3）。